Weekly Top News – IBD – March 9, 2020

etrolizumab (RG7413) / RocheEtrolizumab: Data from P3 BERGAMOT trial (NCT02394028) for moderate-to-severe Crohn's disease in 2021 (Roche, Barclays Global Healthcare Conference 2020) - Mar 13, 2020 [Screenshot]

Ryoncil (remestemcel-L) / Mallinckrodt, Mesoblast, JCR PharmaEvaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease (clinicaltrials.gov) - Mar 10, 2020 - P3; N=330; Completed; Sponsor: Mesoblast, Inc.; Active, not recruiting --> Completed

PN-10-943 / Protagonist Therapeutics; PTG-200 / Protagonist Therapeutics, J&JProtagonist Therapeutics reports fourth quarter and full year 2019 financial results (PRNewswire) - Mar 10, 2020 - "Protagonist Therapeutics and Janssen Biotech are jointly conducting the development of PTG-200 (or JNJ-67864238) through completion of a Phase 2a study in patients with moderate-to-severe Crohn's disease, with the anticipation of completion in the first half of 2021....The Company plans to initiate a Phase 2 study in patients with ulcerative colitis in the second quarter of 2020, with topline data expected in the second half of 2021."

PTG-200 / Protagonist Therapeutics, J&JPTG-200: Patent expiry in US in 2035 (Protagonist Therapeutics) - Mar 11, 2020 - Annual Report 2019

brazikumab (AMG 139) / AllerganOpen-label Extension Study of Brazikumab in Ulcerative Colitis (clinicaltrials.gov) - Mar 11, 2020 - P2; N=300; Enrolling by invitation; Sponsor: Allergan; Not yet recruiting --> Enrolling by invitation

Humira (adalimumab) / Eisai, AbbVieUCanADA: Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis (clinicaltrials.gov) - Mar 10, 2020 - P=N/A; N=100; Completed; Sponsor: AbbVie; Active, not recruiting --> Completed

UTTR1147A / RocheA Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD) (clinicaltrials.gov) - Mar 10, 2020 - P1; N=70; Completed; Sponsor: Genentech, Inc.; Active, not recruiting --> Completed

Xeljanz (tofacitinib) / PfizerXeljanz: Patent expiry in mid-2026 (Cowen & Co. 40th Annual Health Care Conference 2020, Pfizer) - Mar 13, 2020

CERC-002 / Sanofi, Kyowa Hakko Kirin, CerecorCerecor reports 2019 results (GlobeNewswire) - Mar 11, 2020 - "The 2020 organizational focus is driving clinical development programs towards key milestones: CERC-002 (anti-LIGHT mAb) being developed for Pediatric-onset Crohn’s Disease expects initial data readout 2 Half 2020."

Ryoncil (remestemcel-L) / Mallinckrodt, Mesoblast, JCR PharmaEvaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease (clinicaltrials.gov) - Mar 10, 2020 - P3; N=73; Completed; Sponsor: Mesoblast, Inc.; Active, not recruiting --> Completed; N=120 --> 73